Merck and Pfizer to present Avelumab data in seven different cancers at ASCO annual meeting
- Details
- Category: Pfizer
Merck and Pfizer today announced that avelumab* presentations across seven different tumor types, including two oral presentations, will be featured at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2016, in Chicago, IL.
Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
- Details
- Category: Novartis
Novartis has announced changes to focus its Pharmaceuticals Division by creating two business units reporting to the CEO: Novartis Pharmaceuticals and Novartis Oncology. These business units will form the Innovative Medicines Division at Novartis.
Johnson & Johnson announces collaboration with HP Inc. subsidiary to create personalized health care solutions with 3D printing technologies
- Details
- Category: Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) today announced a collaboration between Johnson & Johnson Services, Inc. and a subsidiary of HP Inc. The collaboration is focused on using 3D printing technologies to create better health care outcomes at reduced costs.
Novartis Foundation and partners launch innovative hypertension program in Vietnam
- Details
- Category: Novartis
On the occasion of World Hypertension Day 2016, the Novartis Foundation and its partners, including the international nonprofit organization PATH, are announcing the launch of the Ho Chi Minh City Communities for Healthy Hearts Program, which is designed to improve health outcomes of adults with hypertension living in low-income households in urban Vietnam.
Pfizer awards more than $1 million in metastatic breast cancer research funding
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has awarded a total of more than $1 million in funding to five leading breast cancer advocacy organizations to support projects focused on metastatic breast cancer (MBC) scientific research and quality-of-life studies.
Selumetinib granted Orphan Drug Designation in the US for adjuvant treatment of differentiated thyroid cancer
- Details
- Category: AstraZeneca
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for the investigational MEK 1/2 inhibitor, selumetinib (AZD6244, ARRY-142886) for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer (DTC).
Grants4Apps Accelerator 2016: You imagine, Bayer supports
- Details
- Category: Bayer
The Grants4Apps (G4A) Accelerator developed by Bayer invites health IT and technology startups to apply for the program's 2016 edition. This year, Bayer looks primarily into projects aimed at fostering patient-doctor feedback in the Women's Health field as well as those improving patient engagement in Cardiology, Oncology, Radiology and Ophthalmology, but Bayer is also interested in highly innovative software, hardware, technologies applied to digital health fields.
More Pharma News ...
- AstraZeneca completes acquisition of Takeda's respiratory business
- Ready. Raise. Rise. Campaign
- Pfizer reports first-quarter 2016 results
- Bristol-Myers Squibb reports first quarter financial results
- One family's history of the rare condition Fabry disease through the generations
- What's the secret to living a full life? A new global survey reveals family comes first
- Bayer off to a successful start in 2016